News

B12 Slows Functional Decline in Early-stage ALS, Data Show

Treatment with ultrahigh-dose methylcobalamin — the physiologically active form of vitamin B12 — effectively slowed functional decline in people with early-stage amyotrophic lateral sclerosis (ALS) and moderate progression, data from a small Phase 3 trial in Japan show. The findings confirm previous results from a Phase 2/3 trial and…

NU-9 Is Now AKV9, and Doing Well in Preclinical Studies

AKAVA Therapeutics’ experimental therapy AKV9, formerly NU-9, was superior to approved therapies for amyotrophic lateral sclerosis (ALS) at improving the health of lab-grown upper motor neurons from a mouse model of the disease, a study shows. Upper motor neurons are one of the two types of specialized nerve cells that…

CNM-Au8 Extends Survival, RESCUE-ALS Study Suggests

Treatment with the experimental gold nanocrystal therapy CNM-Au8 decreased the risk of mortality by 64% among people with early amyotrophic lateral sclerosis (ALS), compared to what would be expected without treatment, according to new analyses from the RESCUE-ALS clinical trial. The findings were presented by Clene Nanomedicine,…

Starting Tofersen Early Slows ALS Progression Better: Trial Data

Early use of Biogen’s tofersen significantly slows disability progression, as well as a decline in lung function, muscle strength, and quality of life in amyotrophic lateral sclerosis (ALS) patients with mutations in the SOD1 gene, compared with a six-month delay in starting treatment. These benefits were accompanied by pronounced and sustained…

Dutch Bros Coffee Raises $2.3M for MDA in One Day

Dutch Bros Coffee has long supported efforts from the Muscular Dystrophy Association (MDA) to help patients with amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases and to fund research. It recently outdid itself, though, raising $2.3 million for the organization in a single day. Proceeds from Dutch…